EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nu-Med Plus's enterprise value is $4.28 Mil.
Nu-Med Plus's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.06 Mil. Therefore, Nu-Med Plus's EV-to-EBITDA for today is -67.86.
The historical rank and industry rank for Nu-Med Plus's EV-to-EBITDA or its related term are showing as below:
NUMD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -69.05 Med: 0 Max: 0
Current: -67.86
NUMD's EV-to-EBITDA is ranked worse than 100% of 489
companies
in the Medical Devices & Instruments industry
Industry Median: 15.21
vs NUMD: -67.86
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Nu-Med Plus EV-to-EBITDA Historical Data
The historical data trend for Nu-Med Plus's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nu-Med Plus's EV-to-EBITDA
For the Medical Devices subindustry, Nu-Med Plus's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nu-Med Plus's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nu-Med Plus's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nu-Med Plus's EV-to-EBITDA falls into.
Nu-Med Plus's current Enterprise Value is $4.28 Mil.
Nu-Med Plus's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nu-Med Plus (OTCPK:NUMD) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nu-Med Plus's PE Ratio (TTM) for today is calculated as:
Nu-Med Plus's share price for today is $0.04.
Nu-Med Plus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.001.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Nu-Med Plus's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Nu-Med Plus Inc is a medical device company engaged in the design, innovation, development, enhancement, and commercialization of beginning, early, and selective later-stage quality medical devices. It focuses on the formulation of Nitric Oxide powder, which is a desktop generator device which delivers inhaled Nitric Oxide to replace expensive pressurized canisters and a mobile rechargeable device to deliver inhaled Nitric Oxide gas to offer solutions to hospitals, health systems, and the medical community throughout the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NUMD has been successfully added to your 